Nerolidol attenuates cardiac hypertrophy and fibrosis in mice: Modulation of collagen type I, apoptotic and endothelial gene expression

Articles in Press

Document Type : Original Article

Authors

1 Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan

2 Department of Experimental and Clinical Pharmacology, University of Minnesota, College of Pharmacy, 3-120 Weaver Densford Hall, 308 Harvard St SE, Minneapolis, MN 55455, United States

3 Division of Endocrinology, Diabetes and Metabolism, New York University, Grossmann School of Medicine, New York, USA

4 Department of Basic Medical Sciences, Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

10.22038/ijbms.2026.92642.20001

Abstract

Objective(s): Cardiac hypertrophy is a major pathological feature of cardiovascular disease worldwide. The beneficial effects of terpenes on cardiovascular diseases are well known. In the current study, the cardioprotective effects of nerolidol (NRD), a sesquiterpene alcohol, were evaluated using an isoproterenol (ISO) induced cardiac hypertrophy mice model. 
Materials and Methods: This study was performed by using the chronic subcutaneous infusion model of ISO. Male mice were administered NRD (100 mg/kg) orally for 7 days. On the 8th day with the continuation of NRD dosing, mice received subcutaneous (SC) with ISO (10 mg/kg) for the next 14 days. Cardiac functions, including ejection fraction, cardiac output, and fractional shortening were evaluated by trans-thoracic echocardiography, one day after the final treatment. Then, animals were euthanized and hearts were isolated. The mRNA and protein expressions of cardiac hypertrophy, apoptosis, and fibrosis markers in mice hearts were determined. 
Results: Results showed an increased heart-to-body weight ratio. NRD reduced cardiac hypertrophy by down-regulating the hypertrophic (ANP), apoptotic (Bax/Bcl-2), and fibrotic (Col1a1) markers and prevented cardiac remodeling by up-regulating expression of endothelial nitric oxide synthase (eNOS) and anti-apoptotic (Bcl-xL) protein compared to ISO-treated mice. Combining PCR and western blotting data results demonstrated that NRD reverted the ISO-induced cardiac hypertrophy. 
Conclusion: These findings suggest that NRD prevents ISO-induced cardiac hypertrophy possibly by elevating the levels of eNOS and Bcl-xL and reducing expression of hypertrophic, apoptotic, and fibrotic markers. Thus, NRD may be used to treat ISO-induced cardiac hypertrophy. 

Keywords

Main Subjects

References

1. Abdul Ghani MA, Ugusman A, Latip J, Zainalabidin S. Role of terpenophenolics in modulating inflammation and apoptosis in cardiovascular diseases: A review. Int J Mol Sci 2023; 24: 5339. 
2. Gaidai O, Cao Y, Loginov S. Global cardiovascular diseases death rate prediction. Curr Probl Cardiol 2023; 48: 101622. 
3. Zhao D. Epidemiological features of cardiovascular disease in Asia. JACC Asia 2021; 1: 1–13. 
4. Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R, et al. Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development. Rev Cardiovasc Med 2022; 23:165. 
5. Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric oxide and endothelial dysfunction. Crit Care Clin 2020; 36: 307–321. 
6. Perez-Bonilla P, LaViolette B, Bhandary B, Ullas S, Chen X, Hirenallur-Shanthappa D. Isoproterenol induced cardiac hypertrophy: A comparison of three doses and two delivery methods in C57BL/6J mice. PLoS One 2024; 19: e0307467. 
7. Glumac M, Čikeš Čulić V, Marinović-Terzić I, Radan M. Mechanism of cis-nerolidol-induced bladder carcinoma cell death. Cancers (Basel) 2023; 15: 981. 
8. Baldissera MD, Souza CF, Riéffel RC, Velho MC, Ramos AP, Nascimento K, et al. Protective effect of nerolidol-loaded in nanospheres against cerebral damage caused by Trypanosoma evansi. Naunyn Schmiedebergs Arch Pharmacol. 2018; 391: 753–759. 
9. Fonsêca DV, Salgado PRR, de Carvalho FL, Salvadori MGSS, Penha ARS, Leite FC, et al. Nerolidol exhibits antinociceptive and anti-inflammatory activity: Involvement of the GABAergic system and proinflammatory cytokines. Fundam Clin Pharmacol 2016; 30: 14–22. 
10. Lima DKS, Ballico LJ, Rocha Lapa F, Gonçalves HP, de Souza LM, Iacomini M, et al. Evaluation of the antinociceptive, anti-inflammatory and gastric antiulcer activities of the essential oil from Piper aleyreanum C.DC in rodents. J Ethnopharmacol 2012; 142: 274–282. 
11. Zhao X, Chinnathambi A, Alharbi SA, Natarajan N, Raman M. Nerolidol, bioactive compound suppress growth of hct-116 colorectal cancer cells through cell cycle arrest and induction of apoptosis. Appl Biochem Biotechnol 2024; 196: 1365–1375. 
12. Hammad FT, Al-Salam S, Ahmad R, Yasin J, Hammad AF, Rasheed JA, et al. The effect of nerolidol renal dysfunction following ischemia–reperfusion injury in the rat. Nutrients 2023; 15: 455. 
13. Arroyo JA, Anthony R V, Parker TA, Galan HL. eNOS, NO, and the activation of ERK and AKT signaling at mid-gestation and near-term in an ovine model of intrauterine growth restriction. Syst Biol Reprod Med 2010; 56: 62–73. 
14. Asaikumar L, Vennila L, Akila P, Sivasangari S, Kanimozhi K, Premalatha V, et al. Expression of concern: Preventive effect of nerolidol on isoproterenol induced myocardial damage in Wistar rats: Evidences from biochemical and histopathological studies. Drug Dev Res 2019; 80: 814–823. 
15. Chan WK, Tan L, Chan KG, Lee LH, Goh BH. Nerolidol: A sesquiterpene alcohol with multi-faceted pharmacological and biological activities. Molecules 2016; 21: 529. 
16. Zhang L, Sun D, Bao Y, Shi Y, Cui Y, Guo M. Nerolidol protects against LPS-induced acute kidney injury via inhibiting TLR4/NF-κB Signaling. Phytother Res 2017; 31: 459–465. 
17. Taylor PB, Tang Q. Development of isoproterenol-indued cardiac hypertrophy. Can J Physiol Pharmacol 1984; 62: 384–389. 
18. Maulik SK, Prabhakar P, Dinda AK, Seth S. Genistein prevents isoproterenol-induced cardiac hypertrophy in rats. Can J Physiol Pharmacol 2012; 90: 1117–1125. 
19. Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie R, Sim K, et al. Myocardial oxidative stress contributes to transgenic β 2 ‐adrenoceptor activation‐induced cardiomyopathy and heart failure. Br J Pharmacol 2011; 162: 1012–1028. 
20. Davel AP, Brum PC, Rossoni LV. Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a Giα-coupled β2-adrenoceptor signaling pathway. PLoS One 2014; 9: e91877. 
21. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1–R12. 
22. Xu C, Tang F, Lu M, Yang J, Han R, Mei M, et al. Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways. Int Immunopharmacol 2016; 33: 119–127. 
23. Kempf T, Wollert KC. Nitric oxide and the enigma of cardiac hypertrophy. BioEssays 2004; 26: 608–615. 
24. Liu Y, Afzal J, Vakrou S, Greenland GV, Talbot CC, Hebl VB, et al. Differences in microRNA-29 and pro-fibrotic gene expression in mouse and human hypertrophic cardiomyopathy. Front Cardiovasc Med 2019; 17: 6. 
25. Zhao T, Kee HJ, Bai L, Kim MK, Kee SJ, Jeong MH. Selective HDAC8 inhibition attenuates isoproterenol-induced cardiac hypertrophy and fibrosis via p38 MAPK pathway. Front Pharmacol 2021; 20: 12. 
26. Grant MKO, Abdelgawad IY, Lewis CA, Seelig D, Zordoky BN. Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. PLoS One 2020; 15: e0232507. 
27. Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N, et al. Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 2002; 66:851–856. 
28. Lin Y, Wang L, Xi Y, Li H, Xiao F, Zhao Y, et al. L‐arginine inhibits isoproterenol‐induced cardiac hypertrophy through nitric oxide and polyamine pathways. Basic Clin Pharmacol Toxicol 2008; 103: 124–130. 
29. Lu F, Xing J, Zhang X, Dong S, Zhao Y, Wang L, et al. Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol. Mol Cell Biochem 2013; 381: 41–50. 
30. Gálvez AS, Fiedler JL, Ocaranza MP, Jalil JE, Lavandero S, Díaz-Araya G. Perindopril regulates β-agonist-induced cardiac apoptosis. J Cardiovasc Pharmacol 2005; 46: 255–261. 
31. Zimmer HG. Catecholamine-induced cardiac hypertrophy: Significance of proto-oncogene expression. J Mol Med 1997; 75: 849–859. 
32. Murtuza B, Suzuki K, Bou-Gharios G, Beauchamp JR, Smolenski RT, Partridge TA, et al. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc Natl Acad Sci U S A 2004; 101: 4216–4221. 
33. Takemura G, Fujiwara H. Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 2004; 104: 1–16. 
34. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science (1979). 1998; 281: 1322–1326. 
35. Kirshenbaum LA, de Moissac D. The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation 1997; 96: 1580–1585. 
36. Kashina AS. Regulation of actin isoforms in cellular and developmental processes. Semin Cell Dev Biol 2020; 102: 113–121. 
37. Agostinucci K, Grant MKO, Melaku W, Nair C, Zordoky BN. Exposure to doxorubicin modulates the cardiac response to isoproterenol in male and female mice. Pharmaceuticals 2023; 16: 391. 
38. Zhang L, Ji H, Huang Y, Hu H, Li B, Yang Y, et al. Association of BAX hypermethylation with coronary heart disease is specific to individuals aged over 70. Medicine 2019; 98: e14130. 
39. Perales S, Alejandre MJ, Morales RP, Torres C, Linares A. Fish oil supplementation reverses the effect of cholesterol on apoptotic gene expression in smooth muscle cells. Lipids Health Dis 2010; 9: 70.  
 
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 20 May 2026

Files

Share

How to cite

Statistics